Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRG-110
- Development stage
- Phase 1
- Lead developer
- Viridian Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intradermal
01
Overview
MRG-110 is a locked nucleic acid-modified antisense oligonucleotide designed to inhibit microRNA-92a (miR-92a). By targeting and inhibiting miR-92a, which is known to negatively regulate angiogenesis and tissue repair, MRG-110 promotes the growth of new blood vessels (angiogenesis) and accelerates wound healing. Preclinical studies demonstrated that inhibition of miR-92a by MRG-110 increases vascularization and improves functional outcomes in models of heart failure and wound healing. In clinical trials, administration of MRG-110 led to increased perfusion and histological markers of neoangiogenesis as well as reduced expression of alpha-smooth muscle actin (α-SMA), correlating with decreased activation of myofibroblasts. The drug was developed for potential use in conditions where vascular flow is compromised such as heart failure, ischemia, and wounds[2][3][4][5][7].
- Other names
- MRG-110MRG110MRG 110S95010S-95010S 95010Anti Mir92a
02
Targets
miR-92a-3p (MicroRNA-92a-3p)
Beyond the preview
Go deeper on MRG-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRG-110.